Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)

Next Previous
Trial Profile

RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms AYAME
  • Sponsors Kyowa Kirin

    • Most Recent Events

    • 10 May 2023 Status changed from active, no longer recruiting to discontinued.according to a Kyowa Kirin Co media release.
    • 10 May 2023 According to a Kyowa Kirin Co media release, based on the data of this study and after discussions with key opinion leaders and PMDA, the company has determined that it is difficult to file an application for manufacturing and marketing approval of RTA 402 for diabetic kidney disease in Japan and decided to discontinue the development for this indication.
    • 10 May 2023 Results presented in a media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top